Avidity Biosciences (NASDAQ:RNA) Now Covered by Analysts at Citigroup
Investment analysts at Citigroup began coverage on shares of Avidity Biosciences (NASDAQ:RNA – Get Free Report) in a research report issued to clients and investors on Thursday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $70.00 price target on the biotechnology company’s stock. Citigroup’s price target suggests a potential upside of 125.01% […]
